Fasoracetam – (110958-19-5)

Fasoracetam is a molecule belonging to the racetam family, initially developed for cognitive impairment related to vascular dementia but discontinued due to insufficient efficacy.

It has been repurposed for conditions like ADHD and DiGeorge syndrome, though its effectiveness for ADHD has been limited, particularly in individuals with specific mGluR mutations. Fasoracetam modulates metabotropic glutamate receptors (mGluRs) and has shown cognitive improvement in rodent studies.

Despite its potential, clinical trials have yielded mixed results, and development for most indications has been discontinued. Fasoracetam remains under investigation for DiGeorge syndrome.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Fasoracetam
https://www.medchemexpress.com/fasoracetam.html
https://www.medkoo.com/products/10900
https://psychonautwiki.org/wiki/Talk:Fasoracetam
https://pubmed.ncbi.nlm.nih.gov/29339723/
https://go.drugbank.com/drugs/DB16163